Eisai Licenses T-cell Lymphoma Drug Rights To TSD Japan
This article was originally published in PharmAsia News
Executive Summary
Major Japanese drug maker Eisai on Oct. 26 granted Osaka-based TSD Japan exclusive rights to co-develop the T-Cell Lymphoma drug Ontak (denileukin diftitox) in Japan